


February 15, 2022

Siemens Healthineers AG

Annual Shareholders' Meeting



Virtual Annual Shareholders' Meeting of Siemens Healthineers AG for Fiscal Year 2021

Speech by Prof. Dr. Ralf P. Thomas, Chairman of the Supervisory Board (Summary)

The spoken word shall prevail.

- There is no other word to describe the development of Siemens Healthineers in the past fiscal year than outstanding. I would just like to mention three examples that illustrate this: the acquisition of cancer therapy specialist Varian; the sales of our rapid Covid-19 antigen test; the market approval of the NAEOTOM Alpha, the first computer tomograph based on the innovative fundamental photon-counting technology.
- At the same time, and despite these historic milestones, the company has also been extremely successful from an operational perspective. Revenue was at a record 18 billion euros and we posted record profits of 3.1 billion euros. On behalf of the Supervisory Board, I would like to thank all employees for this outstanding achievement!
- In the second year of the Covid-19 pandemic, the company's senior management has continued to handle the crisis in an excellent way. The physical well-being of our employees has been the top priority governing everything our company's management does. On behalf of the entire Supervisory Board, I'd like to express my sincere gratitude for this.
- Following the completion of the Varian acquisition, Siemens Healthineers is a different company today than it was a year ago. At the start of fiscal year 2022 this "new" company entered a new phase in the company's development which the company calls the "New Ambition" phase. The company has set itself very ambitious goals for this next period, which has been defined until the end of fiscal 2025. The Supervisory Board has been impressed by both the all-embracing nature of the strategy and the sophisticated level of the resulting strategy and financial targets.

- In the past year, the company has also developed and grown in terms of sustainability. So much so that at the end of the fiscal year, the global player and highly reputable company "Sustainalytics" ranked Siemens Healthineers AG fourth out of 195 medical technology companies they evaluated, based on our company's environmental, social and governance (ESG) performance. This achievement is also a huge accolade.
- We have also further developed the management structures of Siemens Healthineers from a corporate law perspective. In September the Supervisory Board elected my colleague Dr. Marion Helmes as independent Chair of the Audit Committee of the Supervisory Board. She takes over from my highly respected colleague Dr. Andreas Hoffmann who will continue to be a member of the Audit Committee, together with me, and for whose commitment on the supervisory bodies I would like to take this opportunity to express my sincere thanks.
- Managing Board Member Dr. Christoph Zindel informed the Supervisory Board in September that for private reasons he would not be available for an extension of his Managing Board mandate. On behalf of the Supervisory Board, I wish to thank Dr. Zindel for his great commitment and achievements in recent years.
- Ms. Elisabeth Staudinger-Leibrecht was appointed by the Supervisory Board to the Managing Board of Siemens Healthineers AG with effect from December 1, 2021. Under her leadership, business in Asia and especially in China has developed excellently. She is a top-ranking manager, an outstanding leader and a recognized Asia expert. Ms. Staudinger-Leibrecht will perform her main duties from the Shanghai office. This will also help us to strengthen the international focus of Siemens Healthineers.
- In fiscal year 2021, the Supervisory Board fulfilled the duties assigned to us by law and the Siemens Healthineers Articles of Association and Bylaws. Discussions at our regular plenary meetings focused on our net assets, financial position and results of operations of Siemens Healthineers, together with its workforce development, and also included the impacts of the Covid-19 pandemic. For further details, I recommend once again that you consult the written Report of the Supervisory Board that describes our work in detail, and which you will find on pages 108 et seq. of the Annual Report.